Read our Recent Headlines


February 12 Biotech Update

The market remains crazy and the sector is filled with odd moves. Yesterday seemed to be a good day of outperformance for the large caps and today they are red.

February 11 Biotech Update

The markets remain in turmoil despite a nice start (but poor finish) yesterday. Interestingly it seemed yesterday at least that large cap biotech outperformed the broader market. Obviously it could.

February 10 Biotech Update

I am glad I was out of the office for the start of the week as the market took a drubbing. While today is certainly starting off better, this is.

Options Basics (4) – Options Strategies

  So far, we discussed all the essential option characteristics. What an option is, its variables, and how to use options for risk adjustment. So now that you know these.

Dave-Trading – PFE

  Pfizer Inc. (PFE)–NYSE   *** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued,.

February 5 Biotech Update

The sector did OK during the pricing hearing but it was more of a mixed bag than across the board out- or under-performance. Today everything is down, so it is.

Options Basics (3) – Options variables and Greeks

  We already discussed what an option is, and how it can help with risk management. When I was talking about risk management, I was talking about how options require a.

Introduction


Quick Facts

10

Analysts

500

Clients

22k

Followers

900

Reports

2.7k

Comments

5

Years

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!